Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled “Bullseye - Targeted Oncology – In with the New” at 10:20 a.m. ET / 7:20 a.m. PT on Tuesday, August 9, 2022.

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after the close of U.S. financial markets on Wednesday, August 3, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2022 Financial Results

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment.

Kura Oncology: Targeting NPM1 Mutations In Acute Myeloid Leukemia

Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ: KURA) to $29 from $27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose for ziftomenib should support an upside of ~$8-10/share to their NPV.

Read Why Did Credit Suisse Raise Price Target On Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Troy Wilson – Chairman and Chief Executive Officer Tom Doyle – Senior Vice President, Finance and Accounting Pete De Spain – Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Jonathan Chang – SVB Securities Peter Lawson – Barclays Corporate & Investment Bank Jonathan Ofertiago – Credit Suisse Roger Song – Jefferies Reni Benjamin – JMP Securities Eva Privitera – Cowen, Inc. Operator Good day and welcome to the Kura Oncology First-Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2022 Results - Earnings Call Transcript

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter –

Kura Oncology Reports First Quarter 2022 Financial Results

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report First Quarter 2022 Financial Results

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor –

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – – Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2021 Results - Earnings Call Transcript

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results after the close of U.S. financial markets on Thursday, February 24, 2022. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 12:40 p.m. PT / 3:40 p.m. ET on Thursday, February 17, 2022.

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

– Expanded leadership team to support and advance the Company's rapid growth – – Expanded leadership team to support and advance the Company's rapid growth –

Kura Oncology Expands Leadership Team with Key Promotions

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML).  The partial clinical hold was lifted following an agreement with the agency on the company's mitigation strategy for differentiation syndrome, an adverse event related to differentiating agents in the treatment of AML.

FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome –

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC –

Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

The stock price of Kura Oncology Inc (NASDAQ: KURA) increased by 4.75% in the most recent trading session. This is why it happened.

Kura Oncology Stock (KURA): Why The Price Increased

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. ("Kura" or the "Company") (NASDAQ: KURA). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML – – New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML –

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

Why Kura Oncology Stock Is Sliding Today

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc's (NASDAQ: KURA) cancer drugs following a patient's death in a clinical trial. Kura reported that the Phase 1b study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probe the death.

See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial

Management to host webcast and conference call today at 8:30 a.m. ET Management to host webcast and conference call today at 8:30 a.m. ET

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call Transcript

News for Kura Oncology Stock (KURA)